Apogee Therapeutics (APGE) Non-Current Assets (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Non-Current Assets data on file, last reported at $219.9 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $219.9 million, up 14.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $643.3 million (down 17.25% YoY), and the FY2025 annual result was $195.8 million, down 12.69% from the prior year.
• Non-Current Assets grew to $219.9 million in Q1 2026 per APGE's latest filing, from $195.8 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $241.8 million in Q3 2024 and troughed at $3.0 million in Q4 2023.
• A 4-year average of $142.7 million and a median of $167.1 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2025: Non-Current Assets surged 7387.08% in 2024, then plunged 64.41% in 2025.
• A 4-year view of Non-Current Assets shows it stood at $3.0 million in 2023, then surged by 7387.08% to $224.2 million in 2024, then dropped by 12.69% to $195.8 million in 2025, then grew by 12.3% to $219.9 million in 2026.
• Business Quant data shows APGE's Non-Current Assets at $219.9 million in Q1 2026, $195.8 million in Q4 2025, and $86.1 million in Q3 2025.